Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

LYFE Capital

Investor type Venture Capital
Founders Drake Yu James Zhao

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 50
Average round size
info
The average size of a deal this fund participated in
$53M
Portfolio companies 39
Rounds per year 5.56
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 1
Key employees 3
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Ansun BioPharma, Burning Rock Biotech, Aohua The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology.

The current fund was established by Drake Yu, James Zhao.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the LYFE Capital, startups are often financed by Legend Star, Sequoia Capital China, Nest.Bio Ventures. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Legend Star, Viventures. In the next rounds fund is usually obtained by Sequoia Capital China, Lilly Asia Ventures, Legend Star.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LYFE Capital:
Typical Co-investors
LYFE Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LYFE Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Genepoint Biological Technology

Health Care
$30M19 Jan 2023 Shanghai, Shanghai, China

Dieshi-DISC

Eyewear
Health Care
Medical
$13M22 Dec 2022 Zhuhai, Guangdong, China

iECURE

Biotechnology
Genetics
$65M30 Nov 2022 Philadelphia, Pennsylvania, United States

MobiDrop

Biopharma
Biotechnology
Health Care
Medical
$13M25 Jul 2022 Hangzhou, Zhejiang, China

ProfoundBio

Biotechnology
Therapeutics
$70M02 Jun 2022 Suzhou, Jiangsu, China

Starna Therapeutics

Biotechnology
Therapeutics
$23M16 May 2022 Suzhou, Jiangsu, China

Aspen Neuroscience

Biotechnology
Medical
Pharmaceutical
Therapeutics
$147M09 May 2022 San Diego, California, United States

Elixir Clinical Research

Biotechnology
Manufacturing
Medical
Pharmaceutical
$52M26 Apr 2022 Shanghai, Shanghai, China

Shenji Bio

$46M11 Apr 2022 Nanjing, Jiangsu, China
News
ABclonal Biotechnology Completes $93 Million Series C Financing

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.

Sciwind Biosciences Secures US$37 Million Series B Financing

– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LYFE Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: